InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces FDA Fast Track Designation for Development of Proprietary MDD Treatment
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for the development of its proprietary investigational nasal spray: PH10. The designation can expedite development of PH10 as a potential treatment of major depressive…